Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era

International Journal of Hematology

Volumn 100, Issue 4, 2014, Pages 386-392

  Uike, Naokuni ^a   Choi, Ilseung ^a   Tsuda, Mariko ^a   Haji, Shojirou ^a   Toyoda, Kousuke ^a   Suehiro, Youko ^a   Abe, Yasunobu ^a   Hayashi, Toshinobu ^a   Sawamoto, Hirofumi ^a   Kaneko, Koichiro ^b   Shimokawa, Mototsugu ^a   Nakagawa, Makoto ^c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b Fukuoka Central Health Evaluation and Promotion Center   (Japan)

^c Koga Hospital   (Japan)

Author keywords

90Y ibritumomab tiuxetan; Factors; Japanese patient; Relapsed or refractory low grade B cell non Hodgkin lymphoma; Rituximab era

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG RESPONSE; EMPYEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; ILEUS; JAPANESE (PEOPLE); JAUNDICE; LARGE CELL LYMPHOMA; LIVER FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHLEGMON; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REFRACTORY LOW GRADE B CELL NON HODGKIN LYMPHOMA; RELAPSED LOW GRADE B CELL NON HODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SALVAGE THERAPY; SECOND CANCER; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TASTE DISORDER; WEIGHT REDUCTION; DISEASE FREE SURVIVAL; LYMPHOMA, B-CELL; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84919658324     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-014-1636-5     Document Type: Article

References (24)

1. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23:1103–8.
2. Colombat PL, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–6.
3. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the german low-grade lymphoma study group. Blood. 2005;106:3725–32.
4. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.
5. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–803.
6. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013;31:1977–83.
7. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9.
8. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanoulides C, Murray JL, et al. Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–70.
9. (90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2005;96:903–10.
10. 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;100:158–64.
11. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
13. US National Institutes of Health. CTCAE/CTC Archive. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_archive
14. Seiler TM, Hiddemann W. Advances in the management of follicular lymphoma. Curr Opin Oncol. 2012;24:742–7.
15. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schider RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804–10.
16. Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, et al. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol. 2010;21:1877–83.
17. Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, et al. Myeloablative doses of Yttrium-90-Ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer. 2011;117:5074–84.
18. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285–92.
19. 90Yttrium-Ibritumomab-Tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31:308–13.
20. 90Y-Ibritumomab Tiuxetan radioimmunotherapy as an Initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014;32:212–8.
21. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (A-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;12:212–8.
22. Yang DH, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, et al. Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:807–11.
23. Briones J, Novellii S, García-Marco JA, Tomás JF, Bernal T, Gramde C, et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematology. 2014;99:505–10.
24. 90Y-ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood. 2011;118:1132–9.